- Home
- CBRE vs EW Comparison
CBRE vs EW Comparison
Compare CBRE & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRE
- EW
- Stock Information
- Founded
- CBRE 1906
- EW 1958
- Country
- CBRE United States
- EW United States
- Employees
- CBRE N/A
- EW 15800
- Industry
- CBRE Real Estate
- EW Industrial Specialties
- Sector
- CBRE Finance
- EW Health Care
- Exchange
- CBRE Nasdaq
- EW Nasdaq
- Market Cap
- CBRE 37.7B
- EW 40.7B
- IPO Year
- CBRE 2004
- EW 2000
- Fundamental
- Price
- CBRE $117.62
- EW $71.53
- Analyst Decision
- CBRE Buy
- EW Buy
- Analyst Count
- CBRE 9
- EW 20
- Target Price
- CBRE $149.56
- EW $78.55
- AVG Volume (30 Days)
- CBRE 2.2M
- EW 4.9M
- Earning Date
- CBRE 04-24-2025
- EW 04-23-2025
- Dividend Yield
- CBRE N/A
- EW N/A
- EPS Growth
- CBRE N/A
- EW 202.39
- EPS
- CBRE 3.14
- EW 6.97
- Revenue
- CBRE $35,767,000,000.00
- EW $5,439,500,000.00
- Revenue This Year
- CBRE $13.51
- EW $10.07
- Revenue Next Year
- CBRE $9.63
- EW $9.65
- P/E Ratio
- CBRE $37.46
- EW $30.57
- Revenue Growth
- CBRE 11.95
- EW 8.57
- 52 Week Low
- CBRE $84.24
- EW $58.93
- 52 Week High
- CBRE $147.75
- EW $95.25
- Technical
- Relative Strength Index (RSI)
- CBRE 39.55
- EW 53.92
- Support Level
- CBRE $115.54
- EW $65.94
- Resistance Level
- CBRE $120.64
- EW $73.26
- Average True Range (ATR)
- CBRE 5.96
- EW 2.44
- MACD
- CBRE -0.28
- EW 0.17
- Stochastic Oscillator
- CBRE 36.30
- EW 76.37
About CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.